pSivida Corp. (NASDAQ:PSDV) reported that it has elected Kristine Peterson, who is a seasoned healthcare executive, to its Board of Directors. Peterson has extensive pharma experience, having worked as the CEO of Valeritas from 2009 to 2016, a commercial-stage medical technology firm focused on simplifying life and improving health for people with diabetes.
She has served as Company Group Chairperson of Johnson & Johnson’s biotech groups from 2006 to 2009, where she oversaw the R&D, commercialization and manufacturing of immunology, oncology and other biotech therapeutics. With Peterson’s election, now the company’s Board strength has become seven, with six directors being independent.
David J. Mazzo, Ph.D., the Chairman of pSivida’s Board, stated that Peterson is a strong commercial and strategic pioneer in the pharmaceutical market and she brings to company a wealth of experience in launching and commercializing products. Peterson success will serve company well as the team prepares to launch Durasert™ 3-year treatment for posterior part uveitis in the U.S., and get partnerships globally.
pSivida’s robust track record of advancing three FDA-permitted sustained-release therapies for back-of-the-eye problems is impressive. Peterson said that she is thrilled to be a part of its upcoming success and look forward to working with team.
Ms. Peterson has healthcare industry experience of more than 30 years. At Valeritas, she was involved in evolving the firm from an early stage firm to a fully commercial operation, after U.S. and EU approved its Type-2 diabetes medicine device. Prior to her role with Company Group Chair at Johnson & Johnson, she was the EVP for Johnson & Johnson (NYSE:JNJ)’s international strategic marketing organization.
She had also worked as SVP, Commercial Operations as well as President with Biovail Corporation. She started her career at Bristol-Myers Squibb Co (NYSE:BMY), where she held many roles in sales, marketing and general management, and was in charge of the metabolic/cardiovascular business division and generics unit.
Besides joining pSivida’s Board, Peterson currently is associated with other advisory and corporate boards., such as Paratek Pharmaceuticals Inc (NASDAQ:PRTK), a biopharmaceutical firm focused on the commercialization and development of innovative therapies grounded upon its expertise in unique tetracycline chemistry.